Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention

{ 'indexed': {'date-parts': [[2024, 4, 25]], 'date-time': '2024-04-25T15:08:50Z', 'timestamp': 1714057730102}, 'reference-count': 49, 'publisher': 'Springer Science and Business Media LLC', 'issue': '6', 'license': [ { 'start': { 'date-parts': [[2020, 8, 11]], 'date-time': '2020-08-11T00:00:00Z', 'timestamp': 1597104000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}, { 'start': { 'date-parts': [[2020, 8, 11]], 'date-time': '2020-08-11T00:00:00Z', 'timestamp': 1597104000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020, 12]]}, 'DOI': '10.1007/s13318-020-00640-6', 'type': 'journal-article', 'created': {'date-parts': [[2020, 8, 11]], 'date-time': '2020-08-11T14:07:32Z', 'timestamp': 1597154852000}, 'page': '715-723', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 13, 'title': 'Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy ' 'and Prevention', 'prefix': '10.1007', 'volume': '45', 'author': [ {'given': 'Mohammad', 'family': 'Tarek', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-0983-3693', 'authenticated-orcid': False, 'given': 'Andrea', 'family': 'Savarino', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2020, 8, 11]]}, 'reference': [ { 'key': '640_CR1', 'volume-title': 'Lexikon bedeutender Chemiker', 'author': 'WR Pötsch', 'year': '1988', 'unstructured': 'Pötsch WR, Fischer A, Müller W. Lexikon bedeutender Chemiker. New Delhi: ' 'Anamika Publishers & Distributors; 1988.'}, { 'key': '640_CR2', 'volume-title': 'Dubois’ lupus erythematosus', 'year': '2007', 'unstructured': 'Wallace DJ, Hahn B, editors. Dubois’ lupus erythematosus. Philadelphia: ' 'Lippincott Williams & Wilkins; 2007.'}, { 'issue': '11', 'key': '640_CR3', 'doi-asserted-by': 'publisher', 'first-page': '722', 'DOI': '10.1016/S1473-3099(03)00806-5', 'volume': '3', 'author': 'A Savarino', 'year': '2003', 'unstructured': 'Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of ' 'chloroquine on viral infections: an old drug against today’s diseases? ' 'Lancet Infect Dis. 2003;3(11):722–7.', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '12', 'key': '640_CR4', 'doi-asserted-by': 'publisher', 'first-page': '1437', 'DOI': '10.4155/fmc.13.113', 'volume': '5', 'author': 'KY Fong', 'year': '2013', 'unstructured': 'Fong KY, Wright DW. Hemozoin and antimalarial drug discovery. Future Med ' 'Chem. 2013;5(12):1437–50.', 'journal-title': 'Future Med Chem'}, { 'issue': '4', 'key': '640_CR5', 'doi-asserted-by': 'publisher', 'first-page': '642', 'DOI': '10.1111/cts.12797', 'volume': '13', 'author': 'SLM Arnold', 'year': '2020', 'unstructured': 'Arnold SLM, Buckner F. Hydroxychloroquine for treatment of SARS-CoV-2 ' 'infection? Improving our confidence in a model-based approach to dose ' 'selection.\xa0Clin Transl Sci. 2020;13(4):642–5. ' 'https://doi.org/10.1111/cts.12797.', 'journal-title': 'Clin Transl Sci'}, { 'key': '640_CR6', 'doi-asserted-by': 'publisher', 'first-page': '105949', 'DOI': '10.1016/j.ijantimicag.2020.105949', 'volume': '20', 'author': 'P Gautret', 'year': '2020', 'unstructured': 'Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, Courjon ' 'J, Giordanengo V, Vieira VE, Dupont HT, Honoré S. Hydroxychloroquine and ' 'azithromycin as a treatment of COVID-19: results of an open-label ' 'non-randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949.', 'journal-title': 'Int J Antimicrob Agents'}, { 'issue': '2', 'key': '640_CR7', 'doi-asserted-by': 'publisher', 'first-page': '259', 'DOI': '10.1097/FTD.0000000000000261', 'volume': '38', 'author': 'S Morita', 'year': '2016', 'unstructured': 'Morita S, Takahashi T, Yoshida Y, Yokota N. Population pharmacokinetics ' 'of hydroxychloroquine in Japanese patients with cutaneous or systemic ' 'lupus erythematosus. Ther Drug Monit. 2016;38(2):259–67.', 'journal-title': 'Ther Drug Monit'}, { 'issue': '6', 'key': '640_CR8', 'doi-asserted-by': 'publisher', 'first-page': '659', 'DOI': '10.1007/s40262-020-00891-1', 'volume': '59', 'author': 'C Smit', 'year': '2020', 'unstructured': 'Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ. Chloroquine for ' 'SARS-CoV-2: implications of its unique pharmacokinetic and safety ' 'properties. Clin Pharmacokinet. 2020;59(6):659–69.', 'journal-title': 'Clin Pharmacokinet'}, { 'key': '640_CR9', 'doi-asserted-by': 'publisher', 'first-page': '106078', 'DOI': '10.1016/j.ijantimicag.2020.106078', 'volume': '4', 'author': 'TJ Oscanoa', 'year': '2020', 'unstructured': 'Oscanoa TJ, Romero-Ortuno R, Carvajal A, Savarino A. A pharmacological ' 'perspective of chloroquine in SARS-CoV-2 infection. Int J Antimicrob ' 'Agents. 2020;4:106078. ' 'https://doi.org/10.1016/j.ijantimicag.2020.106078.', 'journal-title': 'Int J Antimicrob Agents'}, { 'issue': '3', 'key': '640_CR10', 'doi-asserted-by': 'publisher', 'first-page': '406', 'DOI': '10.1128/aac.35.3.406', 'volume': '35', 'author': 'E Pussard', 'year': '1991', 'unstructured': 'Pussard E, Lepers JP, Clavier F, et al. Efficacy of a loading dose of ' 'oral chloroquine in a 36-hour treatment schedule for uncomplicated ' 'plasmodium falciparum malaria.\xa0Antimicrob Agents Chemother. ' '1991;35(3):406–9. https://doi.org/10.1128/aac.35.3.406.', 'journal-title': 'Antimicrob Agents Chemother'}, { 'issue': '4', 'key': '640_CR11', 'doi-asserted-by': 'publisher', 'first-page': '1468', 'DOI': '10.1128/AAC.00339-08', 'volume': '53', 'author': 'HS Lim', 'year': '2009', 'unstructured': 'Lim HS, Im JS, Cho JY, et al. Pharmacokinetics of hydroxychloroquine and ' 'its clinical implications in chemoprophylaxis against malaria caused by ' 'Plasmodium vivax. Antimicrob Agents Chemother. 2009;53(4):1468–75. ' 'https://doi.org/10.1128/AAC.00339-08.', 'journal-title': 'Antimicrob Agents Chemother.'}, { 'issue': '3', 'key': '640_CR12', 'doi-asserted-by': 'publisher', 'first-page': '137', 'DOI': '10.1016/S1386-6532(00)00140-2', 'volume': '20', 'author': 'JR Boelaert', 'year': '2001', 'unstructured': 'Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in ' 'the treatment of HIV-1-infected patients. J Clin Virol. ' '2001;20(3):137–40.', 'journal-title': 'J Clin Virol'}, { 'issue': '9', 'key': '640_CR13', 'doi-asserted-by': 'publisher', 'first-page': '1079', 'DOI': '10.1097/00002030-200006160-00004', 'volume': '14', 'author': 'A Savarino', 'year': '2000', 'unstructured': 'Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38 in HIV-1 ' 'infection: an epiphenomenon of T-cell activation or an active player in ' 'virus/host interactions? Aids. 2000;14(9):1079–89.', 'journal-title': 'Aids'}, { 'issue': '6', 'key': '640_CR14', 'doi-asserted-by': 'publisher', 'first-page': '817', 'DOI': '10.1084/jem.20051106', 'volume': '202', 'author': 'D Accapezzato', 'year': '2005', 'unstructured': 'Accapezzato D, Visco V, Francavilla V, et al. Chloroquine enhances human ' 'CD8+ T cell responses against soluble antigens in vivo. J Exp Med. ' '2005;202(6):817–28.', 'journal-title': 'J Exp Med'}, { 'issue': '9', 'key': '640_CR15', 'doi-asserted-by': 'publisher', 'first-page': '1150', 'DOI': '10.1164/rccm.202003-0524LE', 'volume': '201', 'author': 'D Chang', 'year': '2020', 'unstructured': 'Chang D, Mo G, Yuan X, et al. Time kinetics of viral clearance and ' 'resolution of symptoms in novel coronavirus infection. Am J Respir Crit ' 'Care Med. 2020;201(9):1150–2', 'journal-title': 'Am J Respir Crit Care Med'}, { 'key': '640_CR16', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41422-020-0282-0', 'author': 'M Wang', 'year': '2020', 'unstructured': 'Wang M, et al. Remdesivir and chloroquine effectively inhibit the ' 'recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020. ' 'https://doi.org/10.1038/s41422-020-0282-0.', 'journal-title': 'Cell Res'}, { 'key': '640_CR17', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa237', 'author': 'X Yao', 'year': '2020', 'unstructured': 'Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song ' 'C, Zhan S. In vitro antiviral activity and projection of optimized ' 'dosing design of hydroxychloroquine for the treatment of severe acute ' 'respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. ' 'https://doi.org/10.1093/cid/ciaa237.', 'journal-title': 'Clin Infect Dis'}, { 'key': '640_CR18', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/psp4.12543', 'author': 'A Gonçalves', 'year': '2020', 'unstructured': 'Gonçalves A, Bertrand J, Ke R, Comets E, de Lamballerie X, Malvy D, ' 'Pizzorno A, Terrier O, Rosa Calatrava M, Mentré F, Smith P. Timing of ' 'antiviral treatment initiation is critical to reduce SARS-CoV-2 viral ' 'load. CPT Pharmacometr Syst Pharmacol. 2020. ' 'https://doi.org/10.1002/psp4.12543.', 'journal-title': 'CPT Pharmacometr Syst Pharmacol'}, { 'issue': '33', 'key': '640_CR19', 'doi-asserted-by': 'publisher', 'first-page': '8847', 'DOI': '10.1073/pnas.1704011114', 'volume': '114', 'author': 'K Best', 'year': '2017', 'unstructured': 'Best K, Guedj J, Madelain V, et al. Zika plasma viral dynamics in ' 'nonhuman primates provides insights into early infection and antiviral ' 'strategies. Proc Natl Acad Sci. 2017;114(33):8847–52.', 'journal-title': 'Proc Natl Acad Sci'}, { 'key': '640_CR20', 'doi-asserted-by': 'publisher', 'first-page': '2853', 'DOI': '10.1101/2020.02.29.965418', 'volume': '17', 'author': 'C Li', 'year': '2020', 'unstructured': 'Li C, Xu J, Liu J, et al. The within-host viral kinetics of SARS-CoV-2. ' 'Math Biosci Eng. 2020;17:2853–61. ' 'https://doi.org/10.1101/2020.02.29.965418.', 'journal-title': 'Math Biosci Eng.'}, { 'key': '640_CR21', 'doi-asserted-by': 'publisher', 'DOI': '10.1101/2020.03.23.20040493', 'author': 'KS Kim', 'year': '2020', 'unstructured': 'Kim KS, Ejima K, Ito Y, et al. Modelling SARS-CoV-2 dynamics: ' 'implications for therapy. medRxiv. 2020;. ' 'https://doi.org/10.1101/2020.03.23.20040493.', 'journal-title': 'medRxiv.'}, { 'issue': '10', 'key': '640_CR22', 'doi-asserted-by': 'publisher', 'first-page': 'e1000533', 'DOI': '10.1371/journal.pcbi.1000533', 'volume': '5', 'author': 'L Rong', 'year': '2009', 'unstructured': 'Rong L, Perelson AS. Modeling latently infected cell activation: viral ' 'and latent reservoir persistence, and viral blips in HIV-infected ' 'patients on potent therapy. PLoS Comput Biol. 2009;5(10):e1000533. ' 'https://doi.org/10.1371/journal.pcbi.1000533.', 'journal-title': 'PLoS Comput Biol.'}, { 'issue': '6', 'key': '640_CR23', 'doi-asserted-by': 'publisher', 'first-page': 'e1002774', 'DOI': '10.1371/journal.ppat.1002774', 'volume': '8', 'author': 'IL Shytaj', 'year': '2012', 'unstructured': 'Shytaj IL, Norelli S, Chirullo B, et al. A highly intensified ART ' 'regimen induces long-term viral suppression and restriction of the viral ' 'reservoir in a simian AIDS model.\xa0PLoS Pathog. 2012;8(6):e1002774. ' 'https://doi.org/10.1371/journal.ppat.1002774.', 'journal-title': 'PLoS Pathog.'}, { 'issue': '15', 'key': '640_CR24', 'doi-asserted-by': 'publisher', 'first-page': '7590', 'DOI': '10.1128/JVI.01623-05', 'volume': '80', 'author': 'P Baccam', 'year': '2006', 'unstructured': 'Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of ' 'influenza A virus infection in humans. J Virol. 2006;80(15):7590–9.', 'journal-title': 'J Virol'}, { 'issue': '11', 'key': '640_CR25', 'doi-asserted-by': 'publisher', 'first-page': '1642', 'DOI': '10.1093/infdis/jis265', 'volume': '205', 'author': 'AS Perelson', 'year': '2012', 'unstructured': 'Perelson AS, Rong L, Hayden FG. Combination antiviral therapy for ' 'influenza: predictions from modeling of human infections. J Infect Dis. ' '2012;205(11):1642–5.', 'journal-title': 'J Infect Dis'}, { 'key': '640_CR26', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1186/s13075-020-02211-1', 'volume': '22', 'author': 'H Carlsson', 'year': '2020', 'unstructured': 'Carlsson H, Hjorton K, Abujrais S, Rönnblom L, Åkerfeldt T, Kultima K. ' 'Measurement of hydroxychloroquine in blood from SLE patients using ' 'LC-HRMS—evaluation of whole blood, plasma, and serum as sample matrices. ' 'Arthritis Res Ther. 2020;22:1–9.', 'journal-title': 'Arthritis Res Ther'}, { 'issue': '9', 'key': '640_CR27', 'doi-asserted-by': 'publisher', 'first-page': '1269', 'DOI': '10.1517/13543776.16.9.1269', 'volume': '16', 'author': 'A Savarino', 'year': '2006', 'unstructured': 'Savarino A, Buonavoglia C, Norelli S, Trani LD, Cassone A. Potential ' 'therapies for coronaviruses.\xa0Expert Opin Ther Pat. ' '2006;16(9):1269–88. https://doi.org/10.1517/13543776.16.9.1269.', 'journal-title': 'Expert Opin Ther Pat'}, { 'issue': '3', 'key': '640_CR28', 'doi-asserted-by': 'publisher', 'first-page': '261', 'DOI': '10.1038/s41592-019-0686-2', 'volume': '17', 'author': 'P Virtanen', 'year': '2020', 'unstructured': 'Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, ' 'Burovski E, Peterson P, Weckesser W, Bright J. van der Walt SJ. SciPy ' '1.0: fundamental algorithms for scientific computing in Python. Nat ' 'Methods. 2020;17(3):261–72.', 'journal-title': 'Nat Methods.'}, { 'issue': '2', 'key': '640_CR29', 'doi-asserted-by': 'publisher', 'first-page': '22', 'DOI': '10.1109/MCSE.2011.37', 'volume': '13', 'author': 'SV Walt', 'year': '2011', 'unstructured': 'Walt SV, Colbert SC, Varoquaux G. The NumPy array: a structure for ' 'efficient numerical computation. Comput Sci Eng. 2011;13(2):22–30.', 'journal-title': 'Comput Sci Eng'}, { 'issue': '3', 'key': '640_CR30', 'doi-asserted-by': 'publisher', 'first-page': '90', 'DOI': '10.1109/MCSE.2007.55', 'volume': '9', 'author': 'JD Hunter', 'year': '2007', 'unstructured': 'Hunter JD. Matplotlib: a 2D graphics environment. Comput Sci Eng. ' '2007;9(3):90–5.', 'journal-title': 'Comput Sci Eng'}, { 'key': '640_CR31', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/978-3-319-32726-6', 'volume-title': 'Scaling of differential equations', 'author': 'HP Langtangen', 'year': '2016', 'unstructured': 'Langtangen HP, Pedersen GK. Scaling of differential equations. Berlin: ' 'Springer Nature; 2016. https://doi.org/10.1007/978-3-319-32726-6.'}, { 'key': '640_CR32', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa623', 'author': 'J Fan', 'year': '2020', 'unstructured': 'Fan J, Zhang X, Liu J, et al. Connecting hydroxychloroquine in vitro ' 'antiviral activity to in vivo concentration for prediction of antiviral ' 'effect: a critical step in treating COVID-19 patients. Clin Infect Dis. ' '2020. https://doi.org/10.1093/cid/ciaa623.', 'journal-title': 'Clin Infect Dis.'}, { 'key': '640_CR33', 'doi-asserted-by': 'publisher', 'unstructured': 'Guérin V, Lévy P, Thomas JL, Lardenois T, Lacrosse P, Sarrazin E, de ' 'Andreis NR, Wonner M. Azithromycin and hydroxychloroquine accelerate ' 'recovery of outpatients with mild/moderate COVID-19. Preprints. 2020. ' 'https://doi.org/10.20944/preprints202005.0486.v1.', 'DOI': '10.20944/preprints202005.0486.v1'}, { 'key': '640_CR34', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cpt.1856', 'author': 'M Garcia-Cremades', 'year': '2020', 'unstructured': 'Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka ' 'F, Luetkemeyer AF, Savic RM. Optimizing hydroxychloroquine dosing for ' 'patients with COVID-19: an integrative modeling approach for effective ' 'drug repurposing. Clin Pharmacol Ther. 2020. ' 'https://doi.org/10.1002/cpt.1856.', 'journal-title': 'Clin Pharmacol Ther'}, { 'key': '640_CR35', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1007/s40262-020-00891-1', 'volume': '18', 'author': 'C Smit', 'year': '2020', 'unstructured': 'Smit C, Peeters MY, van den Anker JN, Knibbe CA. Chloroquine for ' 'SARS-CoV-2: implications of its unique pharmacokinetic and safety ' 'properties. Clin Pharmacokinet. 2020;18:1. ' 'https://doi.org/10.1007/s40262-020-00891-1.', 'journal-title': 'Clin Pharmacokinet'}, { 'key': '640_CR36', 'doi-asserted-by': 'publisher', 'unstructured': 'Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in ' 'treatment of patients with common coronavirus disease-19 (COVID-19). J ' 'Zhejiang Univ (Med Sci). Published online March 6, 2020. ' 'https://doi.org/10.3785/j.issn.1008-9292.2020.03.03.', 'DOI': '10.3785/j.issn.1008-9292.2020.03.03'}, { 'issue': '4', 'key': '640_CR37', 'doi-asserted-by': 'publisher', 'first-page': '322', 'DOI': '10.1093/jmcb/mjaa014', 'volume': '12', 'author': 'M Huang', 'year': '2020', 'unstructured': 'Huang M, Tang T, Pang P, Li M, Ma R, Lu J, Shu J, You Y, Chen B, Liang ' 'J, Hong Z. Treating COVID-19 with chloroquine. J Mol Cell Biol. ' '2020;12(4):322–5. https://doi.org/10.1093/jmcb/mjaa014.', 'journal-title': 'J Mol Cell Biol'}, { 'key': '640_CR38', 'doi-asserted-by': 'publisher', 'DOI': '10.5582/bst.2020.01047', 'author': 'J Gao', 'year': '2020', 'unstructured': 'Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown ' 'apparent efficacy in treatment of COVID-19 associated pneumonia in ' 'clinical studies. Biosci Trends. 2020. ' 'https://doi.org/10.5582/bst.2020.01047.', 'journal-title': 'Biosci Trends'}, { 'key': '640_CR39', 'doi-asserted-by': 'publisher', 'unstructured': 'Borba MGS, Almeida Val F, Sampaio VS, et al. Chloroquine diphosphate in ' 'two different dosages as adjunctive therapy of hospitalized patients ' 'with severe respiratory syndrome in the context of coronavirus ' '(SARS-CoV-2) infection: preliminary safety results of a randomized, ' 'double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv. ' 'April 2020. https://doi.org/10.1101/2020.04.07.20056424.', 'DOI': '10.1101/2020.04.07.20056424'}, { 'issue': '12', 'key': '640_CR40', 'doi-asserted-by': 'publisher', 'first-page': '1177', 'DOI': '10.1056/NEJMc2001737', 'volume': '382', 'author': 'L Zou', 'year': '2020', 'unstructured': 'Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, ' 'Xia J, Guo Q. SARS-CoV-2 viral load in upper respiratory specimens of ' 'infected patients. N Engl J Med. 2020;382(12):1177–9.', 'journal-title': 'N Engl J Med'}, { 'key': '640_CR41', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.sapharm.2020.04.016', 'author': 'A Sarayani', 'year': '2020', 'unstructured': 'Sarayani A, Cicali B, Henriksen CH, Brown JD. Safety signals for QT ' 'prolongation or Torsades de Pointes associated with azithromycin with or ' 'without chloroquine or hydroxychloroquine. Res Soc Adm Pharm. 2020. ' 'https://doi.org/10.1016/j.sapharm.2020.04.016.', 'journal-title': 'Res Soc Adm Pharm'}, { 'key': '640_CR42', 'unstructured': 'Boulware D. Post-exposure prophylaxis/preemptive therapy for ' 'SARS-coronavirus-2 (COVID-19 PEP). Minneapolis: University of Minnesota. ' 'https://clinicaltrials.gov/ct2/show/NCT04308668. Accessed 27 Apr 2020.'}, { 'key': '640_CR43', 'doi-asserted-by': 'publisher', 'first-page': '105988', 'DOI': '10.1016/j.ijantimicag.2020.105988', 'volume': '17', 'author': 'SH Lee', 'year': '2020', 'unstructured': 'Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be ' 'considered as one of outbreak response strategies in long-term care ' 'hospitals? Int J Antimicrob Agents. 2020;17:105988. ' 'https://doi.org/10.1016/j.ijantimicag.2020.105988.', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '640_CR44', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa320', 'author': 'P Pagliano', 'year': '2020', 'unstructured': 'Pagliano P, Piazza O, De Caro F, Ascione T, Filippelli A. Is ' 'hydroxychloroquine a possible postexposure prophylaxis drug to limit the ' 'transmission to healthcare workers exposed to coronavirus disease 2019? ' 'Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa320.', 'journal-title': 'Clin Infect Dis'}, { 'key': '640_CR45', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(20)30296-6', 'author': 'N Principi', 'year': '2020', 'unstructured': 'Principi N, Esposito S. Chloroquine or hydroxychloroquine for ' 'prophylaxis of COVID-19. Lancet Infect Dis. 2020. ' 'https://doi.org/10.1016/S1473-3099(20)30296-6.', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '6', 'key': '640_CR46', 'doi-asserted-by': 'publisher', 'first-page': '2684', 'DOI': '10.1128/JVI.80.6.2684-2693.2006', 'volume': '80', 'author': 'YT Yen', 'year': '2006', 'unstructured': 'Yen YT, Liao F, Hsiao CH, Kao CL, Chen YC, Wu-Hsieh BA. Modeling the ' 'early events of severe acute respiratory syndrome coronavirus infection ' 'in vitro. J Virol. 2006;80(6):2684–93.', 'journal-title': 'J Virol'}, { 'key': '640_CR47', 'doi-asserted-by': 'publisher', 'unstructured': 'Gil-Moles M, Basu U, Büssing R, Hoffmeister H, Türck S, Varchmin A, et ' 'al. Gold metallodrugs to fight the corona virus: inhibitory effects on ' 'the SpikeACE2 interaction and on PLpro protease activity by auranofin ' 'and gold organometallics. ChemRxiv. 2020. Preprint. ' 'https://doi.org/10.26434/chemrxiv.12488390.v1.', 'DOI': '10.26434/chemrxiv.12488390.v1'}, { 'issue': '1', 'key': '640_CR48', 'doi-asserted-by': 'publisher', 'first-page': '71', 'DOI': '10.1186/1742-4690-10-71', 'volume': '10', 'author': 'IL Shytaj', 'year': '2013', 'unstructured': 'Shytaj IL, Chirullo B, Wagner W, Ferrari MG, Sgarbanti R, Della Corte A, ' 'LaBranche C, Lopalco L, Palamara AT, Montefiori D, Lewis MG. ' 'Investigational treatment suspension and enhanced cell-mediated immunity ' 'at rebound followed by drug-free remission of simian AIDS. ' 'Retrovirology. 2013;10(1):71.', 'journal-title': 'Retrovirology'}, { 'key': '640_CR49', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.virol.2020.05.002', 'author': 'HA Rothan', 'year': '2020', 'unstructured': 'Rothan HA, Stone S, Natekar J, Kumari P, Arora K, Kumar M. The ' 'FDA-approved gold drug Auranofin inhibits novel coronavirus (SARS-COV-2) ' 'replication and attenuates inflammation in human cells. Virology. 2020. ' 'https://doi.org/10.1016/j.virol.2020.05.002.', 'journal-title': 'Virology'}], 'container-title': 'European Journal of Drug Metabolism and Pharmacokinetics', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s13318-020-00640-6.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s13318-020-00640-6/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s13318-020-00640-6.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 8, 10]], 'date-time': '2021-08-10T23:19:13Z', 'timestamp': 1628637553000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s13318-020-00640-6'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 8, 11]]}, 'references-count': 49, 'journal-issue': {'issue': '6', 'published-print': {'date-parts': [[2020, 12]]}}, 'alternative-id': ['640'], 'URL': 'http://dx.doi.org/10.1007/s13318-020-00640-6', 'relation': { 'has-preprint': [ { 'id-type': 'doi', 'id': '10.1101/2020.04.23.20076471', 'asserted-by': 'object'}]}, 'ISSN': ['0378-7966', '2107-0180'], 'subject': [], 'container-title-short': 'Eur J Drug Metab Pharmacokinet', 'published': {'date-parts': [[2020, 8, 11]]}, 'assertion': [ { 'value': '11 August 2020', 'order': 1, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'No funding source.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Funding'}}, { 'value': 'The authors declare that they have no competing interest.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of interest'}}, { 'value': 'Not applicable.', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethics approval'}}, { 'value': 'Not applicable.', 'order': 5, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Consent to participate'}}, { 'value': 'The authors have consent from their institutions.', 'order': 6, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Consent for publication'}}, { 'value': 'Not applicable.', 'order': 7, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Availability of data and material'}}, { 'value': 'Available at: ExternalRef removed.', 'order': 8, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Code availability'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}]}